Universal Pneumococcal Vaccine Antigen & Serotype Escape Simulator

Vaccine Benchmark Capsular

Global Surveillance Region

Polysaccharide Conjugate Regimen

Conserved Protein Targets Universal

Formulate a multi-antigen cocktail targeting pan-strain sub-capsular epitopes:

PspA Clade 1-2

Family 1 surface protein (Lactoferrin inhibition)

PspA Clade 3-5

Family 2 surface protein (Complement C3 bypass)

PsaA (ABC Transporter)

Manganese permease (99.8% conserved across 100 serotypes)

dPLY Toxoid

Detoxified pneumolysin (Neutralizes hemolytic pore-formation)

CbpA / PspC

Choline-binding adhesin (Factor H mucosal adherence)

Surveillance Telemetry

            PCV20 Initial Coverage
            68.5%
          

            Universal Cocktail Breadth
            98.4%
          

            Year 10 NVT Prevalence
            88.6%
          

Clearance Efficiency 98.4%

Evolutionary Selective Pressure Timeline: Year 10 Surveillance Epoch: 2026–2046

Year 0 (Pre-PCV) Year 5 Year 10 (Replacement Peak) Year 15 Year 20 (Stable Pan-Immunity)

100-Serotype Landscape Matrix (Streptococcus pneumoniae)

Universal Neutralized PCV Suppressed NVT Serotype Escape Unprotected Colonizer

Longitudinal Invasive Pneumococcal Disease (IPD) Burden by Regimen Incidence per 100,000 population

Bacterial Cell Envelope: Capsular Shielding vs Sub-Capsular Epitope Penetration PspA / PsaA / Cell Wall Cross-Section

Scientific Assessment

Recommended Strategy: Multi-antigen conserved protein cocktail (PspA Family 1-2 + PsaA + dPLY) to prevent non-vaccine serotype niche filling.

The Serotype Replacement Dilemma: While conjugate vaccines (PCV13, PCV20) clear target capsular strains with high opsonophagocytic killing (>90%), they create an ecological void. Non-vaccine serotypes (e.g., 15B/C, 23B, 35B) undergo clonal expansion, causing invasive rebound.

Conserved Universal Target Advantage: Protein antigens (PsaA, PspA clades, dPLY) are expressed across virtually all 100 serotypes regardless of polysaccharide capsule structure, circumventing serotype switching and capsular gene loss mutations.

Serotype	PCV20	Universal Breadth	Clinical Risk

Simulation Status ● Engine Ready

D3 v7.9.0 active • Matrix 100/100 isolates • Deterministic stochastic ODE simulation